ES2202228T3 - Metodo para identificar agentes activos contra el hcv usando las coordenadas estructurales de la proteasa del virus de la hepatitis c. - Google Patents

Metodo para identificar agentes activos contra el hcv usando las coordenadas estructurales de la proteasa del virus de la hepatitis c.

Info

Publication number
ES2202228T3
ES2202228T3 ES01101009T ES01101009T ES2202228T3 ES 2202228 T3 ES2202228 T3 ES 2202228T3 ES 01101009 T ES01101009 T ES 01101009T ES 01101009 T ES01101009 T ES 01101009T ES 2202228 T3 ES2202228 T3 ES 2202228T3
Authority
ES
Spain
Prior art keywords
molecule
amino acids
ile
agonist
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01101009T
Other languages
English (en)
Spanish (es)
Inventor
Joseph L. Kim
Kurt A. Morgenstern
Chao Lin
Ted Fox
John A. Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2202228T3 publication Critical patent/ES2202228T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Metallurgy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES01101009T 1996-09-12 1997-09-12 Metodo para identificar agentes activos contra el hcv usando las coordenadas estructurales de la proteasa del virus de la hepatitis c. Expired - Lifetime ES2202228T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2527496P 1996-09-12 1996-09-12
US25274 1996-09-12
US731336 1996-10-18
US08/731,336 US6153579A (en) 1996-09-12 1996-10-18 Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex

Publications (1)

Publication Number Publication Date
ES2202228T3 true ES2202228T3 (es) 2004-04-01

Family

ID=26699520

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01101009T Expired - Lifetime ES2202228T3 (es) 1996-09-12 1997-09-12 Metodo para identificar agentes activos contra el hcv usando las coordenadas estructurales de la proteasa del virus de la hepatitis c.
ES97942450T Expired - Lifetime ES2175462T3 (es) 1996-09-12 1997-09-12 Composiciones cristalizables que comprenden un complejo del dominio de proteasa ns3 del virus de la hepatitis c/ns4a, y cristales asi obtenidos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES97942450T Expired - Lifetime ES2175462T3 (es) 1996-09-12 1997-09-12 Composiciones cristalizables que comprenden un complejo del dominio de proteasa ns3 del virus de la hepatitis c/ns4a, y cristales asi obtenidos.

Country Status (12)

Country Link
US (2) US6153579A (enExample)
EP (1) EP0935609B1 (enExample)
JP (1) JP2001501602A (enExample)
AT (3) ATE244729T1 (enExample)
AU (1) AU736857B2 (enExample)
CA (1) CA2264964A1 (enExample)
DE (3) DE69712085T2 (enExample)
DK (1) DK0935609T3 (enExample)
ES (2) ES2202228T3 (enExample)
IL (1) IL128826A0 (enExample)
PT (2) PT1118619E (enExample)
WO (1) WO1998011134A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
IL143798A0 (en) 1999-01-08 2002-04-21 Bristol Myers Squibb Co Hepatitis c virus ns3 protease
US6524589B1 (en) * 1999-04-08 2003-02-25 Schering Corporation Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
JP2003511467A (ja) 1999-10-14 2003-03-25 ブリストル−マイヤーズ スクイブ カンパニー アンドロゲンレセプターリガンド結合ドメインの結晶構造
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
HUP0303172A3 (en) 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1334179A2 (en) 2000-11-14 2003-08-13 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells lsi-01
CA2443393A1 (en) 2001-04-03 2002-11-07 Bristol-Myers Squibb Company Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
US20030027315A1 (en) * 2001-09-24 2003-02-06 Ada Yonath Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals
US20050009877A1 (en) * 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ES2389201T3 (es) 2003-10-27 2012-10-24 Vertex Pharmaceuticals Incorporated Mutantes de resistencia de la proteasa NS3/4A de HCV
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
NZ568324A (en) 2005-11-11 2012-01-12 Vertex Pharma Hepatitis C virus variants
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP2009531315A (ja) * 2006-03-16 2009-09-03 バーテックス ファーマシューティカルズ インコーポレイテッド 重水素化ｃ型肝炎プロテアーゼインヒビター
US8440443B1 (en) 2006-05-16 2013-05-14 Merck Sharp & Dohme Corp. MEK1 polypeptides
EA200970806A1 (ru) 2007-02-27 2010-08-30 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
US8575208B2 (en) 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2436682A1 (en) 2007-08-30 2012-04-04 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8988881B2 (en) * 2007-12-18 2015-03-24 Sandia Corporation Heat exchanger device and method for heat removal or transfer
US9005417B1 (en) 2008-10-01 2015-04-14 Sandia Corporation Devices, systems, and methods for microscale isoelectric fractionation
US9795961B1 (en) 2010-07-08 2017-10-24 National Technology & Engineering Solutions Of Sandia, Llc Devices, systems, and methods for detecting nucleic acids using sedimentation
US9261100B2 (en) 2010-08-13 2016-02-16 Sandia Corporation Axial flow heat exchanger devices and methods for heat transfer using axial flow devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
US5353236A (en) * 1992-04-23 1994-10-04 The Board Of Trustees Of The Leland Stanford University High-resolution crystallographic modelling of a macromolecule
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.

Also Published As

Publication number Publication date
US6153579A (en) 2000-11-28
IL128826A0 (en) 2000-01-31
US6303287B1 (en) 2001-10-16
DK0935609T3 (da) 2002-07-22
CA2264964A1 (en) 1998-03-19
DE69712085T2 (de) 2002-11-28
JP2001501602A (ja) 2001-02-06
AU4414597A (en) 1998-04-02
WO1998011134A1 (en) 1998-03-19
DE69736995D1 (de) 2007-01-04
DE69736995T2 (de) 2007-09-20
ES2175462T3 (es) 2002-11-16
HK1038573A1 (en) 2002-03-22
EP0935609B1 (en) 2002-04-17
ATE216400T1 (de) 2002-05-15
DE69723485D1 (de) 2003-08-14
EP0935609A1 (en) 1999-08-18
AU736857B2 (en) 2001-08-02
ATE346088T1 (de) 2006-12-15
DE69712085D1 (de) 2002-05-23
HK1022700A1 (en) 2000-08-18
PT935609E (pt) 2002-09-30
ATE244729T1 (de) 2003-07-15
PT1118619E (pt) 2003-11-28
DE69723485T2 (de) 2004-05-27

Similar Documents

Publication Publication Date Title
US6303287B1 (en) Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
Kim et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide
Upadhyay et al. Crystal structure of full-length Zika virus NS5 protein reveals a conformation similar to Japanese encephalitis virus NS5
CN100457776C (zh) 丙型肝炎病毒ns5b聚合酶抑制剂结合袋
Love et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site
Biswal et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors
Yao et al. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease–helicase
Yan et al. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 Å resolution structure in a hexagonal crystal form
US7894996B2 (en) Structure of the hepatitis C NS5A protein
US7438920B1 (en) Crystals of hepatitis C virus helicase or fragments thereof comprising a helicase binding pocket
ES2141081T5 (es) Nuevo aislado de hcv j-1.
US20020042046A1 (en) Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
ES2273934T5 (es) Antígeno del virus de la hepatitis no a, no b, métodos diagnósticos y vacunas.
Yi et al. Delineation of regions important for heteromeric association of hepatitis C virus E1 and E2
Izumida et al. Purification of hepatitis C virus core protein in non-denaturing condition
Shoji et al. Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coli
US6434489B1 (en) Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same
US6524589B1 (en) Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
Kang et al. Crystallization and preliminary X-ray crystallographic analysis of the helicase domain of hepatitis C virus NS3 protein
EP1118619B1 (en) Method to identify agents active against HCV by using the structure coordinates of hepatitis C virus protease
EP1364961B1 (en) Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained
US10753939B2 (en) HCV NS4a/modified NS3 polypeptides and uses thereof
HK1059792A (en) Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained
HK1038573B (en) Method to identify agents active against hcv by using the structure coordinates of hepatitis c virus protease
HK1022700B (en) Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained